Heron Therapeutics(US:HRTX)2023-03-24 04:49Product Performance & Sales - ZYNRELEF demand units increased by 38% from Q3'22 to Q4'22[6] - APONVIE launched on March 6, 2023, targeting the PONV prevention market[2, 45] - CINV Franchise net sales increased to $97.5 million in 2022[15] - Total net product sales for the year ended December 31, 2022, were $107.7 million[1, 76] Market & Strategy - ZYNRELEF targets 74 IDNs, representing a potential $149 million Exparel sales opportunity[8] - ZYNRELEF offers acquisition cost savings of 23% to 34% compared to Exparel[13] - APONVIE targets a large market opportunity of 36 million annual procedures in patients at moderate to high risk for PONV[14] Financial Status - Heron had $84.9 million in cash, cash equivalents, and short-term investments as of December 31, 2022[49] - Full-year 2023 CINV Franchise net sales are expected to be in the range of $99 million to $103 million[48] Product Development - A Vial Access Needle (VAN) is being developed to simplify ZYNRELEF withdrawal, with potential availability by mid-2024[20] - A prefilled syringe (PFS) for ZYNRELEF is under development[20, 87]